Who
Robert James Wills
Director
Company insider
Files Form 4 as: Director, Alpha Cognition; Director, Milestone Pharmaceuticals; Executive Chairman, Oncternal Therapeutics; Director, CymaBay Therapeutics.
In numbers
- Trades disclosed
- 74
- Buys
- 13
- Sells
- 1
- Bought
- $811K
- Sold
- $8,859
- Companies
- 4
- Companies where not an officer
- 3
- First trade
- 2 Mar 2015
- Last trade
- 21 Aug 2026
- Last filed
- 24 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 21 Aug 2026filed 24 Aug 2026 | ACOG Alpha CognitionBiotechnology | SEC FORM 4 Bought | $96K10,000 at $9.62 | filing |
| 21 Aug 2026filed 24 Aug 2026 | ACOG Alpha CognitionBiotechnology | SEC FORM 4 Bought | $96K10,000 at $9.62 | filing |
| 10 Jun 2026filed 12 Jun 2026 | MIST Milestone Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —77,000 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | MIST Milestone Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —77,000 at $0.00 | filing |
| 14 Jan 2026filed 16 Jan 2026 | ACOG Alpha CognitionBiotechnology | SEC FORM 4 Code A | —7,241 at $0.00 | filing |
| 14 Jan 2026filed 16 Jan 2026 | ACOG Alpha Cognitionoption or derivative · Biotechnology | SEC FORM 4 Code A | —8,437 at $0.00 | filing |
| 14 Jan 2026filed 16 Jan 2026 | ACOG Alpha Cognitionoption or derivative · Biotechnology | SEC FORM 4 Code A | —8,437 at $0.00 | filing |
| 14 Jan 2026filed 16 Jan 2026 | ACOG Alpha CognitionBiotechnology | SEC FORM 4 Code A | —7,241 at $0.00 | filing |
| 18 Aug 2025filed 21 Aug 2025 | ACOG Alpha CognitionBiotechnology | SEC FORM 4 Bought | $127K15,000 at $8.49 | filing |
| 11 Jul 2025filed 15 Jul 2025 | MIST Milestone Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 | filing |
| 11 Jul 2025filed 15 Jul 2025 | MIST Milestone Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 | filing |
| 11 Jul 2025filed 15 Jul 2025 | MIST Milestone PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —50,000 | filing |
| 10 Jun 2025filed 12 Jun 2025 | MIST Milestone Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 7 Apr 2025filed 9 Apr 2025 | ACOG Alpha Cognitionoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,019 at $0.00 | filing |
| 28 Aug 2024filed 29 Aug 2024 | MIST Milestone Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 20 Jun 2024filed 24 Jun 2024 | Oncternal Therapeuticsoption or derivative | SEC FORM 4 Code A | —2,200 at $0.00 | filing |
| 8 Apr 2024filed 10 Apr 2024 | Oncternal Therapeutics | SEC FORM 4 Bought | $28K3,086 at $8.96 | filing |
| 28 Mar 2024filed 1 Apr 2024 | Oncternal Therapeutics | SEC FORM 4 Bought | $59K6,914 at $8.48 | filing |
| 22 Mar 2024filed 22 Mar 2024 | CymaBay Therapeuticsoption or derivative | SEC FORM 4 Code D | —18,000 | filing |
| 22 Mar 2024filed 22 Mar 2024 | CymaBay Therapeuticsoption or derivative | SEC FORM 4 Code D | —25,000 | filing |
News
Alpha Cognition Announces Publication of U.S. Patent Application Relating to Proprietary Manufacturing Process for ZUNVEYL®ACOG · standard-freeholder.com · 13 Oct 2026Alpha Cognition Inc. (NASDAQ:ACOG) Stock Now Rated "Buy" by Sell-Side BrokeragesACOG · dailypolitical.com · 13 Oct 2026
0 headlines in the last 90 days name Robert James Wills; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.